Co-diagnostics, inc. to amend q2 2020 form 10-q to show $0.51 net income per share

Salt lake city, utah, nov. 2, 2020 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that following the discovery of an incorrectly recorded expense in...

CODX Ratings Summary

CODX Quant Ranking